Dr Reddy's Laboratories has confirmed to have received an establishment inspection report (EIR) from the US health regulator after an audit of its UK facility. "With regard to the audit of our API Mirfield plant, United Kingdom, we would now like to inform you that we have received an establishment inspection report (EIR) from the USFDA, for the above-referred facility, indicating closure of the audit," Dr Reddy's said in a regulatory filing.
The USFDA issues an EIR to the establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection.
The US health regulator had last year made three observations after inspecting Dr Reddy's Laboratories' API Mirfield plant, United Kingdom.
Shares of Dr Reddy's Laboratories were trading at Rs 2,170.35 apiece on BSE, up 1.71 per cent from the previous close.
